Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity

Geeta A. Lalwani, Audina Berrocal, Timothy G. Murray, Maria Buch, Scott Cardone, Ditte Hess, Rose A. Johnson, Carmen A. Puliafito

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

PURPOSE: To report the short term anatomic response of intravitreal bevacizumab (Avastin, Genentech) as salvage treatment in progressive retinopathy of prematurity (ROP) in a small series of patients. METHODS: The study included five eyes of three patients with progressive ROP despite peripheral laser ablation. Patients received intravitreal injections of bevacizumab (Avastin, Genentech). RetCam (Clarity Medical Systems, Inc., Pleasanton, CA) photography and ultrasonography were used to document effect. RESULTS: Three patients were transferred to the Bascom Palmer Eye Institute/Jackson Memorial Hospital for management of progressive ROP despite laser therapy at an outside facility. RetCam fundus photography and ultrasonography were used to document all cases. After informed consent was obtained from the parents, the patients received off-label intravitreal bevacizumab as salvage treatment. Repeat intravitreal injections of bevacizumab were utilized in several cases. The ROP stabilized allowing laser supplementation. There was varying development of tractional retinal detachments in several of the eyes but the ROP component quieted in all cases. CONCLUSIONS: Off-label use of bevacizumab appears to be useful as a salvage treatment for ROP when laser treatment is precluded. It improves dilation, quiets the disease when visibility is difficult, and temporizes the disease until laser can be supplemented.

Original languageEnglish
JournalRetina
Volume28
Issue number3 SUPPL.
DOIs
StatePublished - Mar 1 2008

Fingerprint

Off-Label Use
Salvage Therapy
Retinopathy of Prematurity
Intravitreal Injections
Lasers
Photography
Laser Therapy
Ultrasonography
Retinal Detachment
Bevacizumab
Informed Consent
Dilatation
Parents

Keywords

  • Alvage treatment
  • Anti-EGF therapy
  • Etinopathy of prematurity
  • Evacizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. / Lalwani, Geeta A.; Berrocal, Audina; Murray, Timothy G.; Buch, Maria; Cardone, Scott; Hess, Ditte; Johnson, Rose A.; Puliafito, Carmen A.

In: Retina, Vol. 28, No. 3 SUPPL., 01.03.2008.

Research output: Contribution to journalArticle

Lalwani, Geeta A. ; Berrocal, Audina ; Murray, Timothy G. ; Buch, Maria ; Cardone, Scott ; Hess, Ditte ; Johnson, Rose A. ; Puliafito, Carmen A. / Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. In: Retina. 2008 ; Vol. 28, No. 3 SUPPL.
@article{b4b7b0454a194bac8ecf329a294450e2,
title = "Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity",
abstract = "PURPOSE: To report the short term anatomic response of intravitreal bevacizumab (Avastin, Genentech) as salvage treatment in progressive retinopathy of prematurity (ROP) in a small series of patients. METHODS: The study included five eyes of three patients with progressive ROP despite peripheral laser ablation. Patients received intravitreal injections of bevacizumab (Avastin, Genentech). RetCam (Clarity Medical Systems, Inc., Pleasanton, CA) photography and ultrasonography were used to document effect. RESULTS: Three patients were transferred to the Bascom Palmer Eye Institute/Jackson Memorial Hospital for management of progressive ROP despite laser therapy at an outside facility. RetCam fundus photography and ultrasonography were used to document all cases. After informed consent was obtained from the parents, the patients received off-label intravitreal bevacizumab as salvage treatment. Repeat intravitreal injections of bevacizumab were utilized in several cases. The ROP stabilized allowing laser supplementation. There was varying development of tractional retinal detachments in several of the eyes but the ROP component quieted in all cases. CONCLUSIONS: Off-label use of bevacizumab appears to be useful as a salvage treatment for ROP when laser treatment is precluded. It improves dilation, quiets the disease when visibility is difficult, and temporizes the disease until laser can be supplemented.",
keywords = "Alvage treatment, Anti-EGF therapy, Etinopathy of prematurity, Evacizumab",
author = "Lalwani, {Geeta A.} and Audina Berrocal and Murray, {Timothy G.} and Maria Buch and Scott Cardone and Ditte Hess and Johnson, {Rose A.} and Puliafito, {Carmen A.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1097/IAE.0b013e3181644ad2",
language = "English",
volume = "28",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity

AU - Lalwani, Geeta A.

AU - Berrocal, Audina

AU - Murray, Timothy G.

AU - Buch, Maria

AU - Cardone, Scott

AU - Hess, Ditte

AU - Johnson, Rose A.

AU - Puliafito, Carmen A.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - PURPOSE: To report the short term anatomic response of intravitreal bevacizumab (Avastin, Genentech) as salvage treatment in progressive retinopathy of prematurity (ROP) in a small series of patients. METHODS: The study included five eyes of three patients with progressive ROP despite peripheral laser ablation. Patients received intravitreal injections of bevacizumab (Avastin, Genentech). RetCam (Clarity Medical Systems, Inc., Pleasanton, CA) photography and ultrasonography were used to document effect. RESULTS: Three patients were transferred to the Bascom Palmer Eye Institute/Jackson Memorial Hospital for management of progressive ROP despite laser therapy at an outside facility. RetCam fundus photography and ultrasonography were used to document all cases. After informed consent was obtained from the parents, the patients received off-label intravitreal bevacizumab as salvage treatment. Repeat intravitreal injections of bevacizumab were utilized in several cases. The ROP stabilized allowing laser supplementation. There was varying development of tractional retinal detachments in several of the eyes but the ROP component quieted in all cases. CONCLUSIONS: Off-label use of bevacizumab appears to be useful as a salvage treatment for ROP when laser treatment is precluded. It improves dilation, quiets the disease when visibility is difficult, and temporizes the disease until laser can be supplemented.

AB - PURPOSE: To report the short term anatomic response of intravitreal bevacizumab (Avastin, Genentech) as salvage treatment in progressive retinopathy of prematurity (ROP) in a small series of patients. METHODS: The study included five eyes of three patients with progressive ROP despite peripheral laser ablation. Patients received intravitreal injections of bevacizumab (Avastin, Genentech). RetCam (Clarity Medical Systems, Inc., Pleasanton, CA) photography and ultrasonography were used to document effect. RESULTS: Three patients were transferred to the Bascom Palmer Eye Institute/Jackson Memorial Hospital for management of progressive ROP despite laser therapy at an outside facility. RetCam fundus photography and ultrasonography were used to document all cases. After informed consent was obtained from the parents, the patients received off-label intravitreal bevacizumab as salvage treatment. Repeat intravitreal injections of bevacizumab were utilized in several cases. The ROP stabilized allowing laser supplementation. There was varying development of tractional retinal detachments in several of the eyes but the ROP component quieted in all cases. CONCLUSIONS: Off-label use of bevacizumab appears to be useful as a salvage treatment for ROP when laser treatment is precluded. It improves dilation, quiets the disease when visibility is difficult, and temporizes the disease until laser can be supplemented.

KW - Alvage treatment

KW - Anti-EGF therapy

KW - Etinopathy of prematurity

KW - Evacizumab

UR - http://www.scopus.com/inward/record.url?scp=43149101294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149101294&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181644ad2

DO - 10.1097/IAE.0b013e3181644ad2

M3 - Article

VL - 28

JO - Retina

JF - Retina

SN - 0275-004X

IS - 3 SUPPL.

ER -